Actively Recruiting
Phase III Study of ONC-PluReceptor NK Cell Therapy Combined with Epcoritamab and Tafasitamab for Adults with Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
Led by M.D. Anderson Cancer Center · Updated on 2026-05-01
30
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What this Trial Is About
This research aims to evaluate the use of ONC-PluReceptor natural killer NK cell therapy combined with the monoclonal antibodies epcoritamab and tafasitamab in adults with relapsed or refractory B-cell Non-Hodgkin lymphoma that expresses CD19 or CD20 markers. The study focuses on establishing the safety and the best dose for this treatment, as well as measuring how well it controls the lymphoma, including response rates and survival times. Participants will receive umbilical cord blood-derived NK cells modified with ONC-PluReceptor, delivered by injection and combined with the two antibody therapies. The trial includes dose escalation and dose expansion phases to find the recommended treatment dose. Treatment cycles will be administered under medical supervision, with monitoring for safety and response. Throughout the study, participants will undergo assessments including tumor biopsies, blood tests, and scans to monitor immune response, side effects, and disease progression. Safety and adverse events will be tracked for about one year, and immune system recovery will be studied. Participants are expected to be followed for long-term effects and treatment outcomes, with the total duration depending on individual responses.
CONDITIONS
Brief Title
Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
Research Team
Y
Yago Nieto, MD,PHD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
